Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
暂无分享,去创建一个
[1] W. Hiddemann,et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.
[2] R. Gelber,et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] H. Sather,et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. G. Hoffman,et al. Cytosine arabinoside/cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia. Potential selective effect in T‐cell leukemia , 1987, Cancer.
[5] M. Schrappe,et al. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. , 1987, Haematology and blood transfusion.
[6] H. Sather,et al. Prolonged second remissions in childhood acute lymphocytic leukemia: a report from the Childrens Cancer Study Group. , 1983, Medical and pediatric oncology.